Moxifloxacin - ntuziaka maka ọrụ

Nkọwa dị mkpa maka ya 30.01.2015

• Aha Latin: Moxifloxacine
• Koodu ATX: J01MA14
• Arụ Ọrụ: Moxifloxacin (Moxifloxacin)
• Emeputa: Vertex (Russia), Macleods Pharmaceutical (India).

1 mbadamba moxifloxacin hydrochloride 400 mg

Cellulose, lactose monohydrate, hydroxypropyl cellulose, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, talc, iron oxide na-acha ọbara ọbara, dị ka ndị na-emebu ọgwụ.

Pharmacodynamics na pharmacokinetics

Mlọ ọgwụ

Ọgwụ antibacterial sitere na otu nke ọgbọ IV nke quinolones (trifluoroquinolone), na-eme nje. Penetrates n'ime sel nke pathogen na egbochi n'otu oge enzymetinyere aka na ntụgharị nke DNA na ịchịkwa Njirimara nke DNA, nke na-eduga mgbanwe dị ukwuu na mgbidi sel, mebie DNA na ọnwụ nke pathogen.

Ihe ngosi Moxifloxacin ọgwụ njeime ihe n'ihe banyere nje ọrịa intracellular, gram-positive na gram-microorganisms. Irè megide anaerobes, acid na-eguzogide ọgwụ na nje na-efe efe. Ọ bụ otu n'ime ọrụ na-emegide staphylococci, gụnyere staplelococci na-egbochi methicillin. N'ime ọrụ mycoplasmas dị elu Levofloxacinna chlamydia - Ofloxacin.

Ọ dịghị nguzogide na penisilini, aminoglycosides, macrolidesna cephalosporins. Ugboro nke nguzogide ọgwụ ọgwụ dị ala, nguzogide na-amalite nwayọ. Ọgwụ ahụ enweghị mmetụta na-eme ka ikike gwụ. Mmetụta nke ọgwụ ahụ bụ ihe kwekọrọ kpọmkwem na itinye uche ya na ọbara yana anụ ahụ ma nwee ntakịrị mmesapụ aka na-eso ya toxinsyabụ enweghi ọghọm nke mmepe mmenaanya megidere usoro ọgwụgwọ.

Mlọ ọgwụ

Moxifloxacin mgbe nchịkwa ọnụ zuru oke. Bioavailability bụ 91%. A na-ahụta ọgwụ kachasị na ọgwụ mgbe awa 0.5-4 gachara, mgbe ụbọchị atọ nke ị regularụbiga ya ike, ọ na-enweta ọkwa ya kwụ chịm. A na-ekesa ọgwụ ahụ na akwara, ma na-ekpebi ihe dị ukwuu n'ime ya na usoro iku ume yana anụ ahụ. Oge T 1/2 - 12 awa. Ọ bụ ya mere akụrụ na site na ngwara nri.

Ihe ngosi maka ojiji

• Erkwara nta (yana ọgwụ ndị ọzọ na-akpata TB, dị ka ọgwụ nke abụọ),
• ọrịa iku ume: hr ọla kọpa na ogbo di oke, sinusitis, oyi baa,
• intra-abdominal na urogenital ofufe,
• na-efe efe nke anụ ahụ na anụ ahụ dị nro.

Ihe ngbanwe

• dị arọ imeju imeju,
• hypersensitivity
• ọnya na-efe efe,
• afọ ruo afọ 18
• na-ebido inwe ọdịdọ,
• tụụrụ ime.

Ejiri nlezianya de C ka ọ bụrụ ogologo oge nke Q-T, ischemia myocardial, bradycardia dị mkpa, hypokalemia, ka ị na-ewere corticosteroids.

Nsonaazụ

• Ihe mgbu isi, ọgbụgbọ, afọ ntachi,ọnụ ọgụgụ nke transaminases, ọnụ akọrọ, anorexia, candidiasis mẹ onyẹ alịgastritis, dysphagia,mgbanwe asụsụ
• ire ure, asthenia, ehighi ura, isi ọwụwa, mmetụta ụjọ, paresthesia. Ọ dị ụkọ - anaghị ekwu okwu ikwu okwu, hallucinations, cramps,ndaba,
• mgbanwe uto ma ọ bụ mfu nke mmetụta uto,
• tachycardiaobi mgbu, mụbaa EGOOge etiti Q-T na-agbatịkwu,
• mkpụkpu umeadịkarịghị - ọdịdọ ụkwara ume ọkụ,
• arthralgiaazu mgbu
• ọgvu kandụlọrụ ezughi oke,
• akwara, urticaria,
• leukopenia, eosinophilia, anaemia, thrombocytosis, hyperglycemia.

Mmekorita

Antacids, multivitaminsya na mineral na Ranitidine ime ka uru ahụ kwụsịlata ma belata ịta ọgwụ dị na plasma. Ekwesịrị inye ha ọgwụ awa 2 ka ha takingụchara ọgwụ ọgwụ. Nkwadebe ígwè, ihe na-agbanwe agbanwe Ekwesịrị iji usoro bioavailability belata, a ga-eji ya ma elekere asatọ gachaa.

Oge ndị ọzọ ji eme ya quinolonesenwekwu ohere ịgbatị oge nke Q-T ọtụtụ oge. Moxifloxacin nwere obere ọgwụ ọgwụ Digoxin.

Mgbe na-ewere Warfarin ịkwesịrị ijikwa ndị na-egosi coagulation. Mgbe nnabata corticosteroids ịbawanye n'ihe ọghọm akaịịịịịịịịịịịịịịịịịị n'ihu n'ihu na ihu akaị roagụ.

Ngwongwo ogwu

Mlọ ọgwụ

Moxifloxacin bụ ọgwụ nje nke na - egbochi nje bacteria na - egbochi 8-methoxyphoroquinolone. Mmetụta bactericidal nke moxifloxacin bụ n'ihi mgbochi nke topoisomerases nje na nke II, nke na-eduga na-emeghasịkwa usoro nke ịmụgharị, ndozi na ntinye nke biosynthesis DNA nke mkpụrụ ndụ microbial na, n'ihi ya, ọnwụ nke mkpụrụ ndụ microbial.
Obere ihe ncheta nke moxifloxacin bụ moxifloxacin na-adịkarị site na iji obere mkpokọta inhibitory (MIC).
Zọ nguzogide

Usoro ndị na-eduga na mmepe nke iguzogide penisiliniins, cephalosporins, aminoglycosides, macrolides na tetracyclines adịghị emetụta ọrụ antibacterial nke moxifloxacin. Onweghi nguzogide n'etiti otu ndia nke ogwu nje na moxifloxacin. Ruo ugbu a, enwebeghịkwa ikpe metụtara mgbochi plasmid. Oge mmepe nke nguzogide dị obere (10 -7 -10 -10). Ndọgide moxifloxacin na-amalite nwayọ nwayọ site na mmụkọ ọ bụla. Mmetụta ugboro ugboro nke moxifloxacin na microorganisms na mkpokọta n'okpuru MIC bụ naanị ntakịrị mmụba na MIC. Ekwuru okwu nke nguzogide nguzogide na quinolones. Na agbanyeghị, ụfọdụ microorganisms gram-positive na anaerobic microorganisms na-eguzogide na quinolones ndị ọzọ ka nwere moxifloxacin.
E guzobere ya na mgbakwunye na nke methoxy otu n'ime ọnọdụ C8 na moxifloxacin molecule moulifloxacin na-eme ka ọrụ moxifloxacin belata ma guzobe ụdị nje nje na-eguzogide ọgwụ. Ihe mgbakwunye nke otu ndi bikcloamine na ebe C7 na-egbochi mmepe nke efflux dị ike, usoro nke iguzogide fluoroquinolones.
Moxifloxacin in vitro arụ ọrụ megide ọtụtụ gram-na-adịghị mma na microorganisms, anaerobes, nje na-eguzogide acid na nje na-efe efe dị ka Mycoplasma spp., Chlamydia spp., Legionella $ pp.yana nje ndị na-eguzogide ọgwụ mgbochi ß-lactam na macrolide.
Mmetụta na microflora eriri afọ mmadụ

N'ime ọmụmụ abụọ emere na ndị ọrụ afọ ofufo, a hụrụ mgbanwe ndị a na microflora eriri afọ bụ mgbe nchịkwa ọnụ nke moxifloxacin. Nchoputa nke onu ogugu kwuru. Escherichia coli, Bacillus spp., Bacteroides vulgatus, Enterococcus spp., Klebsiella spp.yana anaerobes Bifidobacterium spp., Eubacterium spp., Peptostreptococcus spp. A gbanwere mgbanwe ndị a n'ime izu abụọ. Ọgwụ Clostridium mgbasa ahụghị.
Na Nnwale Nnwale nke Vitro

Ihe dị iche iche na-egbochi nje bacteria na-akpata moxifloxacin gụnyere microorganisms ndị a:

Nnọọ mmetụta	Ọ dịtụ nro	Na-eguzogide
Odi mma
Gardnerella vaginalis
Ahụ ike na-efe efe (gụnyere ụdị na-eguzogide penisilini na nje nwere ọtụtụ ọgwụ mgbochi), yana ụdị na-eguzogide ọgwụ abụọ ma ọ bụ karịa, dị ka penisilini (MIC> 2 mg / ml), II cephalosporins II (dịka cefuroxime), macrolides, tetracyclines, trimethoprim / sulfamethoxazole
Ike pyogenes (otu A) *
Otu a Streptococcus milleri (S. anginosus * S. constellatus * na interrnedius *)
Otu a Ptomụ nwanyị na-amaghị nwoke Streptococcus (S. amaghị nwoke, S. mutans, S. mitis, S. sanguinis, S. salivarius, S. thermophilics, S. constellatus)
Ike komboliscoccus
Streptococcus dysgalactiae
Staphylococcus aureus (gụnyere ụdị ọrịa metụtara methicillin) *	Staphylococcus aureus (methicillin / ofloxacin nje na-egbochi) *
Coagulonegative Staphylococci (S .. cohnii, S. epidermic! Bụ, S. haemolyticus, S. hominis, S. saprophytic us, S s ​​imulans)nsogbu methicillin nwere mmetụta	Onye na-eme Coagul staphylococci (S.cohnii, S. epidermic / bụ, S. haemolyticus, S. opi dị na, S.saprophytics, S. simulans)ụdị methicillin na-eguzogide ọgwụ
Enterococcus faecalis* (naanị ụdị nwere nsogbu nke vancomycin na gentamicin)
Enterococcus avium *
Enterococcus faecium *
Gram odi njo
Haemophilus influenzae (gụnyere ụdị na-emepụta ß-lactamases na - anaghị emepụta) *
Haemophillus parainfluenzae*
Moraxella catarrhalis (gụnyere ụdị na-emepụta ß-lactamases na - anaghị emepụta) *
Bordetella pertussis
Legionella pneumophila	Escherichia coli *
Acinetobacter baumanii	Klebsiella ka oyi baa
Klebsiella oxytoca
Citrobacter freundii *
Enterо bader spp. (E.aerogenes, E.intermedins, E.sakazakii))
Enterobacter cloacae *
Pantoea agglomerans
Pseudomonas aeruginosa
Pseudomonas fluorescens
Burkholderia cepacia
Stenotrophomonas maltophilia
Proteus mirabilis *
Nkwa nzuzo
Morganella morganii
Neisseria gonorrhoeae *
Providencia spp. (P. rettgeri, P. Stuartii)
Anaerobes
Bacteroides spp. (B.fragi / bu * B. Distasoni * Na thetaiotaomicron *, B. ovatus *, B. edobe bụ *, B. vulgaris *)
Fusobacterium spp.
Peptos treptococcus spp. *
Porphyromonas spp.
Prevotella spp.
Propionibacterium spp.
Clostridium spp. *
Aty
Chlamydia na oyi baa
Chiamydia trachomatis *
Mycoplasma pneumoniae *
Mycoplasma hominis
Mycoplasma genitalium
CoxieIla burnettii
Legionella pneumohila

* Ihe nchoputa maka moxifloxacin ka egosiputara site na data nke ulo ogwu.

Ekwesighi iji moxifloxacin maka ọgwụgwọ nke ọrịa ọrịa methicillin na-akpata S. aureus (MRSA). Ọ bụrụ na ndị ọrịa MRSA enyo enyo ma ọ bụ gosipụtara na ọ kpatara, a ga-edenye ọgwụgwọ maka ọgwụ nje ndị kwesịrị ekwesị.
Maka ụfọdụ nsogbu, mgbasa mgbasa enweta enweta nwere ike ịdị iche site na mpaghara ala na oge karịa. N'akụkụ a, mgbe ị na-anwale ụdị akwara ahụ, ọ dị mma ịnweta ozi mpaghara gbasara nguzogide, ọkachasị mgbe a na-agwọ ọrịa ndị siri ike.
Ọ bụrụ na n’ime ndị ọrịa a na-anara ọgwụgwọ n’ụlọ ọgwụ, mpaghara dị n’okpuru oge ịchekwa ọgwụ ọgwụ (AUC) / MHK₉₀ gafere 125, na mkpokọta plasma kachasị (Cmax) / MIC₉₀ dị na etiti 8-10 - nke a na-egosi imeziwanye ọgwụ. N'ime ndị ọrịa, parammita ndị a na-agbadata na-adịkarị ala: AUC / MIC₉₀>30-40.

Oke (nkezi uru)	AUIC * (h)	Cmax / MIC90 (infusion maka 1 awa)
MIC90 0.125 mg / ml	313	32,5
MIC90 0.25 mg / ml	156	16,2
MIC90 0,5 mg / ml	78	8,1

* AUIC - mpaghara dị n'okpuru usoro mgbochi (akara (AUC) / MMK)₉₀).

Mlọ ọgwụ
Egwu
Mgbe otu infusion nke moxifloxacin na dose nke 400 mg maka 1 h, C max na-erute na njedebe nke infusion na ihe dị ka 4.1 mg / l, nke kwekọrọ na mmụba nke ihe dị ka 26% ma e jiri ya tụnyere ọnụ ahịa nke ihe ngosi a mgbe ị na-ewere moxifloxacin n'ọnụ. Nkpughari nke moxifloxacin, nke onye gosiputa AUG kpebisiri ike, ji ntakịrị karie nke nchịkwa ọnụ nke moxifloxacin. Nnukwu bioavailability dị ihe dịka 91%. Mgbe ugboro ugboro infusions intravenous infusions nke moxifloxacin na dose nke 400 mg maka 1 awa, kacha na kacha nta na-anọchi ihe anya sitere na 4.1 mg / L ruo 5.9 mg / L na site na 0.43 mg / L ruo 0.84 mg / L, kwekọrọ. A na-enweta ihe nkwụsi ike nke 4.4 mg / L na njedebe nke mkpụrụ.
Nkesa
A na - ekesa Moxifloxacin ngwa ngwa na akwara na akwara ma na - egbochi ihe nchebe ọbara (ọkachasị albumin) ihe dịka 45%. Olu nke nkesa dị ihe dịka 2 l / n'arọ.
Moxifloxacin dị elu, karịa ndị nọ na plasma ọbara, na-ekepụta na ngụgụ ngụgụ (gụnyere epithelial fluid, alveolar macrophages), na sinuses (maxillary na ethmoid sinuses), na polyps imi, na mmebi nke mbufụt (na ọdịnaya nke blisters na ọnya anụ ahụ). Na mmiri etiti, na ọgwụ mmiri, a na-ekpebi moxifloxacin n'ụdị n'efu, na-abụghị protein, na mkpo dị elu karịa na plasma ọbara. Na mgbakwunye, moxifloxacin nwere nnukwu anụ ahụ na akwara akụkụ nke akụkụ afọ, na mmiri ara, yana akụkụ akụkụ nke nwanyị.
Metabolism
Moxifloxacin na-enyocha biotransformation nke agba nke abụọ ma ewepụta ya n'ahụ site na akụrụ na eriri afọ ya abụọ, anaghị agbanwe agbanwe na n'ụdị sulfo sulfo na-adịghị arụ ọrụ (Ml) na glucuronides (M2).
Moxifloxacin abụghị biotransform site na sistemụ microsomal cytochrome P450. Metabolites Ml na M2 dị na plasma ọbara n'ọbara dị ala karịa ogige nne na nna. Dabere na nsonaazụ nke usoro ọmụmụ, a gosipụtara na metabolites ndị a enweghị mmetụta na-adịghị mma n'ahụ ahụ n'ihe gbasara nchekwa na ịnagide ihe.
Ojiji
Nkeji ọkara moxifloxacin bụ ihe dị ka awa 12. Igosi nkenke nhichapụ mgbe ọ nwesịrị ọgwụ dị 400 mg bụ 1 79-246 ml / min. Mkpochapu ntaramahụhụ bụ 24-53 ml / min. Nke a na-egosi ntughari akwara tubular nke moxifloxacin.
Ighazi maka mmalite na usoro nke metabolites abụọ dị ihe dịka 96-98%, nke na-egosi enweghị metabolism oxidative. Ihe dịka 22% nke otu ọgwụ (400 mg) na-agbanwegharị site na akụrụ, ihe dịka 26% - site na eriri afọ.
Pharmacokinetics na otu ọrịa dị iche iche
Afọ, nwoke na nwanyị
Nnyocha nke ọgwụ ọgwụ moxifloxacin na ụmụ nwoke na ụmụ nwanyị kpughere ọdịiche nke 33% na usoro nke AUC na Cmax .. Mwepu moxifloxacin abụghị nke nwoke. Ọdịiche dị na AUC na Cmax bụ n'ihi ihe dị iche n'etiti oke ahụ karịa nke nwoke na nwanyị na-adịchaghị mkpa ọgwụgwọ.
Enweghị ọdịiche dị oke mkpa dị na ọgwụ ọgwụ nke moxifloxacin na ndị ọrịa nke agbụrụ dị iche iche na afọ dị iche iche.
Childrenmụaka
Emebeghị ka ogwu ọgwụ nke moxifloxacin na ụmụaka.
Odida ntaramahụhụ
Onweghi mgbanwe di nkpa na pharmacokinetics nke moxifloxacin na ndi ọrịa nwere nsogbu gbasara akwara ndi mmadu (tinyere ndi okachasi mekwaa nke 2) na ndi oria na anagide onodu a na –ebu agha na outpatient outitoneal ruo ogologo oge.
Ọrụ imeju na-arụ ọrụ
Enweghị ọdịiche dị mkpa na ịta moxifloxacin na ndị ọrịa nwere ọrụ imeju na-arụ ọrụ (-mụaka Purt klaasị A na B) ma e jiri ya tụnyere ndị ọrụ afọ ofufo nwere ahụike na ndị ọrịa nwere ọrụ imeju nkịtị (maka iji na ndị ọrịa nwere ọrịa metụtara ọrịa, leekwa akụkụ "ntuziaka pụrụ iche" )

Usoro onunu ogwu na nhazi

Usoro akwadoro usoro nke moxifloxacin: 400 mg (250 ml nke ihe maka infusion) oge 1 kwa ụbọchị yana oria a egosipụtara n’elu. Agafela dose a tụrụ aro.
Oge ọgwụgwọ

Ogologo oge ọgwụgwọ ahụ kpebiri site na ọnọdụ yana ogo nke ọrịa ahụ, yana nsonaazụ ụlọ ọgwụ.

• Oria pneumonia nke obodo mepụtara: ngụkọta oge nke ọgwụgwọ a na-eji moxifloxacin (nchịkwa ọgbụgba sochiri nchịkwa ọnụ) bụ ụbọchị 7-14,
• Ọrịa jikọtara ọnụ nke anụ ahụ na nkebi subcutaneous: ngụkọta oge nke ọgwụ ọgbụgba na moxifloxacin bụ ụbọchị 7-21,
• Ọrịa ọgbụgba na-agbadata ime: ngụkọta oge nke ọgwụ ọgbụgba na moxifloxacin bụ 5-14 ụbọchị.

Agafela oge ọgwụgwọ a tụrụ aro ya. Dika ihe omumu nke ulo ogwu, oge ọgwụgwọ na moxifloxacin nwere ike iru ubochi iri abuo na abuo.
Ndị okenye na-arịa ọrịa

Notgbanwe usoro onunu ogwu n’ebe ndi agadi no achoghi.
Childrenmụaka

E guzobeghị ịdị adị na nchekwa nke ojiji moxifloxacin na ụmụaka na ụmụaka.
Ọrụ imeju na-arụ ọrụ (andmụaka na ụmụ klas L na B)

Ndị ọrịa nwere nsogbu imeju adịghị mkpa ịgbanwe usoro onunu ogwu (maka iji na ndị ọrịa nwere ọrịa imeju, lee ngalaba “Ntuziaka Pụrụ Iche”).
Odida ntaramahụhụ

N'ime ndị ọrịa nwere ọrụ akwara nwere nsogbu (gụnyere ndị nwere nnukwu akụrụ gbasara akwara na mwepụ nke 30 ml / min / 1.73 m 2), yana ndị ọrịa na-aga usoro ọgwụgwọ na-aga n'ihu na usoro ọgwụgwọ ogologo oge, usoro ọgwụgwọ anaghị achọ ihe. .
Jiri na ndị ọrịa nke agbụrụ dị iche iche

Notgbanwe usoro usoro usoro onunu ogwu achoghi.
Ofzọ nke ngwa

A na-ahụ maka ọgwụ ahụ n'ọrịa nke infusion na-adigide ma ọ dịkarịa ala minit 60, ma etinyere ya yana ngbanye usoro ndị a kwekọrọ na ya (iji ihe nkwụnye T-eme ihe):

• mmiri maka ịgba ntụtụ
• 0.9% sodium chloride solution,
• 1M sodium chloride solution,
• 5% dextrose,
• 10% dextrose ngwọta,
• 40% dextrose ngwọta,
• 20% xylitol,
• azịza ringer
• laringate ngwọta

Ọ bụrụ na ọgwụ moxifloxacin, ihe ngwọta maka infusion, na-eji ya na ọgwụ ndị ọzọ, mgbe ahụ, ekwesịrị ịnye ọgwụ ọ bụla iche.
Ngwakọta nke ọgwụ ogwu na ngwakọta infusion dị n'elu na-akwụsi ike ruo awa 24 n'ụlọ okpomọkụ.
Ebe ọ bụ na enweghị ike ịta oyi ma ọ bụ jụọ oyi, enweghị ike ịchekwa ya na friji. Mgbe imetachara ihe, oke nwere ike ibute nke na-agbari n'ime ụlọ ụlọ. Ekwesịrị ịchekwa ihe edozi na ngwugwu ya. Naanị ihe doro anya ga-eji.

Mmetụta akụkụ

Cangaghị abanye ngbanye infusion nke moxifloxacin n’otu oge yana usoro ndị ọzọ ekwekọghị na ya, nke gụnyere:

• 10% sodium chloride solution,
• 20% sodium chloride solution,
• 4.2% sodium bicarbonate ngwọta,
• 7.4% sodium bicarbonate ngwọta.

Ntụziaka pụrụ iche

Mmetụta ikike ịkwọ ụgbọala na usoro

Fluoroquinolones, gụnyere moxifloxacin, nwere ike imebi ikike nke ndị ọrịa ịkwọ ụgbọala na itinye aka na ihe egwu ndị ọzọ nwere ike ịchọrọ nlebara anya na ọsọ nke mmeghachi omume psychomotor n'ihi nsonaazụ na sistemụ akwara na imerụ ahụ.

Emeputa

Mpempe akwụkwọ Mpempe akwụkwọ
LLC PROMOMA RUS, Russia,
101000, Moscow, Arkhangelsky Lane, 1, ụlọ 1

Adreesị iwu:
Russia, Republic of Mordovia,
430030, Saransk, st. Vasenko, 1 5A.

Adreesị ebe a na-emepụta ihe:
Russia, Republic of Mordovia,
430030, Saransk, st. Vasenko, 15A.

Aha, adreesị na akara ekwentị ekwentị nke nzukọ enyere maka kọntaktị (izipu mkpesa na mkpesa):
LLC PROMOMA RUS, Russia,
129090, Moscow, Prospect Mira, 13, p.

Ngwakọta na ụdị ntọhapụ

Moxifloxacin dị n'ụdị atọ: ngwọta maka infusion, mbadamba maka nchịkwa ọnụ na ọdịda anya. Ihe mejupụtara ha:

Ọgwụ na-acha odo odo Biconvex

Rationta nke moxifloxacin hydrochloride, mg

Iron oxide, calcium stearate, titanium dioxide, ọka ọka, talc, croscarmellose sodium, macrogol, polyvinyl mmanya, mannitol, opadra, microcrystalline cellulose, povidone, hydroxypropyl cellulose, hypromellose, polyethylene glycol.

Sodium Chloride, Sodium Hydroxide, hydrogen nke Acid, Mmiri

Sodium hydroxide, sodium chloride, hydrochloric acid, boric acid, mmiri

Blisters maka 5 PC., 1 ma ọ bụ 2 blisters na mkpọ

Karama 250 ml

5 Mpekere anwụrụ polyethylene

Usoro onunu ogwu na nhazi

Dị ọgwụ dị iche iche maka ịhapụ ọgwụ dịgasị iche iche. Mbadamba mbadamba nkume ndị ahụ bu n'uche maka nchịkwa ọnụ, a na-edozi ọgwụ a ngwa ngwa, a na-etinye ọnya mmiri ahụ n'anya yana ọrịa na-efe efe kwekọrọ. Usoro ọgwụgwọ na-adabere n'ịdị ogo ọrịa ahụ, ụdị ya, njirimara onye ọrịa ahụ. Enyere ozi na ntuziaka.

N’oge ime ime

Mgbe ị na-amụ nwa, ị takingụ ọgwụ nje na-egbochi imebi ya, ọ gwụkwala ma uru nne ya eruteghị na nsogbu ọ bụla. Emebeghị nnyocha banyere nchekwa nke ọgwụ n'oge afọ ime. Mgbe ị na-edepụta ọgwụ n'oge a na-enye ya ara, a ga-akagbu inye nwa ya ara, n'ihi na arụ ọrụ nke ihe mejupụtara ya banye na mmiri ara ara ma na-emetụta ahụike nke nwa ahụ.

Mkparịta ụka ọgwụ ọjọọ

Tupu ịmalite ọgwụgwọ na Moxifloxacin, mmekọrịta nke ọgwụ na ọgwụ ndị ọzọ kwesiri ịmụ. Njikọ na nsonaazụ:

1. Antacids sitere na magnesium ma ọ bụ aluminom hydroxide, sucralfate, zinc na nhazi nke ígwè na-ebelata ọgwụ a.
2. Ogwu ahụ na-abawanye oke digoxin, belata arụ ọrụ nke glibenclamide.
3. Ranitidine na-ebelata nnabata nke ọgwụ nje n'ime ọbara, nwere ike ibute candidiasis.
4. Nchikota nke ogwu ahu na fluoroquinolones ndi ozo, Penicillin na-abawanye mmeghachi omume phototoxic.

Dodoụbiga ya ókè

Ọbara mmetụta nke ọgwụ nje na-apụta site na mmụba ọ na-akpata. Mgbe ịdoụbiga mmanya ókè, ị ga-asacha afọ, kwụsị ị takingụ ọgwụ ọjọọ, jiri sọks wepụ ihe na-egbu egbu (Smecta, carbon carbon, Enterosgel, Sorbex). Xxụbiga mmanya ókè, a na-anabata nchịkwa mgbochi nke ọgwụgwọ mgbochi, iji ọgwụ Symptomatic, a na-anabata ọgwụ mgbochi.

Omume ọgwụ

Moxifloxacin bụ ọgwụ nje nke na-egbochi nje bacteria na ọtụtụ ụdị fluoroquinolone. Moxifloxacin na-egosipụta ọrụ na vitro megide ọtụtụ ụdị-gram-positive na gram na-adịghị mma, anaerobic, acid na-eguzogide ọgwụ na-adịghị efe efe, dịka ọmụmaatụ Chlamidia spp., Mycoplasma spp. na Legionella spp. Mmetụta nke ọgwụ nje na-akpata n'ihi mgbochi nke topoisomerases nje na nke II, nke na-eduga ná mmebi nke biosynthesis nke DNA nke sel microbial na, n'ihi ya, na ọnwụ nke mkpụrụ ndụ microbial. Obere ihe nje nje na -echekarị nke ọgwụ ọgwụ na-adịkarị site na iji obere mkpokọta mgbochi ya.

Moxifloxacin nwere nsị nke nje na-egbochi nje na - egbochi ọgwụ mgbochi lactam na macrolides.

Usoro ndị na-eduga na mmepe nke iguzogide penisiliniins, cephalosporins, aminoglycosides, macrolides na tetracyclines anaghị emebi ọrụ antibacterial nke moxifloxacin. Onweghi nguzogide n'etiti otu ndia nke ogwu nje na moxifloxacin. Achọpụtabeghị ihe mgbochi nke Plasmid. Ọnụnọ nke nguzogide dị obere (10 '- 10 ") Nguzogide moxifloxacin na-amalite nwayọ nwayọ site na mmụba mmụba. Mgbapụta ugboro ugboro nke moxifloxacin na microorganisms na mkpokọta n'okpuru ntakịrị inhibitory ịta (MIC) na-esonyere naanị ntakịrị mmụba na MIC. E nwere ikpe nke obe na-eguzogide quinolones. Na agbanyeghị, ụfọdụ microorganisms gram-positive na anaerobic microorganisms na-eguzogide na quinolones ndị ọzọ ka nwere moxifloxacin.

Ihe dị iche iche na-egbochi nje bacteria na-akpata moxifloxacin gụnyere microorganisms ndị a:

1. gram-mma - streptococcus pneumoniae (gụnyere nje eguzogide penicillin na macrolides na mwute na otutu iguzogide ọgwụ nje) *, streptococcus pyogenes (Group A) *, streptococcus milleri, streptococcus mitis, streptococcus agalactiae *, streptococcus dysgalactiae, streptococcus anginosus *, Stullococcus constellatus *, Staphylococcus aureus (gụnyere methicillin na-eme ka ọnụnọ) *, Staphylococcus cohnii, staphylococcus epidermidis (gụnyere methicillin na-akpata nsogbu), staphylococcus haemolyticus, Staphylocococococococococococococococococococococo na-echebara vancomycin na gentamicin) *.

2. Gram-negative - Haemophillus influenzae (gụnyere ụdị na-emepụta ma na-anaghị emepụta (3-lactamases) *, Haemophillus parainfluenzae *, Klebsiella pneumoniae *, Moraxella catarrhalis (gụnyere ụdị na-emepụta ma na-anaghị emepụta (3-lactamases) *, Escherobacteria coli * , Bordetella pertussis, Klebsiella oxytoca, Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter intermedius, Enterobacter tizaki, Proteus mirabilis *, Proteus vulgaris, Morganella morganii, Providencia rettgeri, Providencia stuartii.

3. anaerobes - Bacteroides distasonis, Bacteroides eggerthii, Bacteroides fragilis *, Bacteroides ovatum, Bacteroides thetaiotaomicron *, Bacteroides uniformis, Fusobacterium spp, Peptostreptococcus spp *, Porphyromonas spp, Porphyromonas anaerobius, Porphyromonas asaccharolyticus, Porphyromonas Magnus, Prevotella spp, .... Propionibacterium spp., Clostridium perfringens *, Clostridium ramosum.

4. Atypical - Chlamydia pneumoniae *, Mycoplasma pneumoniae *,

Legionella pneumophila *, Coxiella bumetti.

* - enwere ike gosipụta uche na moxifloxacin site na data nyocha.

Moxifloxacin adịghị arụ ọrụ megide Pseudomonas aeruginosa, Pseudomonas fluorescens, Burkholderia cepacia, Stenotrophomonas maltophilia.

Mlọ ọgwụ

Mgbe otu infusion moxifloxacin na dose nke 400 mg maka 1 awa, ịta ọgwụ kachasị (C_tah) a na-enweta ya na ngwụsị nke infusion ma dị ihe dịka 4.1 mg / l, nke kwekọrọ na mmụba dị ihe dịka 26% ma e jiri ya gosipụta uru ihe ngosi a mgbe ị na-a theụ ọgwụ n'ime. Nkpughepu ogwu ahu, nke ndi AUC kpebiri (mpaghara n’okpuru oge nlebara anya), kariri nke ahuru mgbe ị na-a theụ ọgwụ ahụ n’ime. Nnukwu bioavailability dị ihe dịka 91%.

Mgbe ugboro ugboro intravenous infusions nke ihe ngwọta nke moxifloxacin na a dose nke 400 mg maka 1 awa, ọnụ ọgụgụ kasị elu na plasma itinye uche na steeti kwụsiri ike (400 mg otu ugboro kwa ụbọchị) rute ụkpụrụ site na 4.1 ruo 5.9 mg / l yana site na 0.43 ruo 0.84 mg / l, n’otu n’otu. Na steeti kwụsiri ike, nsonaazụ nke moxifloxacin na etiti oge usoro onunu ogwu dị ihe dịka 30% karịa nke mbụ. A na-enweta ngụkọta ngụkọta nke 4.4 mg / L na njedebe nke mkpụrụ.

A na - ekesa Moxifloxacin ngwa ngwa na akwara na akwara ma na - egbochi ihe nchebe ọbara (ọkachasị albumin) ihe dịka 45%. Olu nke nkesa dị ihe dịka 2 l / n'arọ.

Moxifloxacin na-enyocha biotransformation nke oge nke abụọ ma na - ahụ ya site na ahụ site na akụrụ ya, yana yana anụ ahụ na-agbanwe agbanwe, na-agbanwe agbanwe na n'ụdị sulfo na-eme sulfo na glucuronides. Moxifloxacin abụghị biotransform site na sistemụ microsomal cytochrome P450. Ọkara ọkara nke ọgwụ ahụ bụ ihe dịka awa 12. Nkezi mkpochapu mgbe agwachara ya na onwa ogwugwo 400 mg si na 179 ruo 246 ml / min. Ihe dịka 22% nke otu ọgwụ (400 mg) na-agbanwegharị na mmamịrị ahụ, ihe dịka 26% - na ọnya.

Nchedo nchekwa

N'ụfọdụ, mgbe ojiji nke moxifloxacin mbụ, hypersensitivity na mmeghachi omume nfụkasị nwere ike ịmalite. Ọ dịkarịghị ala, mmeghachi omume anaphylactic nwere ike ịga n'ihu na ihe atụ nke ndụ anaphylactic, ọbụlagodi mgbe ị firstụ ọgwụ mbụ. N'ụdị ndị a, ekwesịrị ịkwụsị moxifloxacin yana usoro ọgwụgwọ dị mkpa (gụnyere mgbochi ụjọ).

Site n'iji moxifloxacin na ụfọdụ ndị ọrịa, enwere ike ịchọpụta ndọtị nke QT.

Nyere na ụmụ nwanyị na-agbatịkwu oge nke QT ma e jiri ya tụnyere ndị nwoke, ha nwere ike ịdị na-eche banyere ọgwụ na-agbatị oge Qt. Ọrịa ndị agadi na-enwekarị mmetụta dị mma maka ọgwụ ndị na-emetụta oge QT.

Ogo ịgbatị oge nke oge QT nwere ike ịbawanye elu site na ị increasingụ ọgwụ ọfụma, yabụ ị ga-agafe ọkwa achọrọ na ọnụego infusion (400 mg na nkeji 60). Agbanyeghị, na ndị ọrịa nwere oyi baa enweghị njikọ n'etiti ịta moxifloxacin na plasma ọbara na ịgbatị nke etiti QT. Associatedgbatị oge nke QT na-esonye n'ihe egwu dịwanye elu nke arrhythmias, gụnyere polymorphic ventricular tachycardia. Ọ dịghị onye n'ime ndị ọrịa 9,000 e mesoro moxifloxacin nwere nsogbu obi ma ọ bụ okwu ikpe metụtara ịgbatị ogologo oge nke QT. Agbanyeghị, na ndị ọrịa nwere ọnọdụ na-ekwu maka arrhythmias, iji moxifloxacin nwere ike ịbawanye ohere nke ventricular arrhythmias.

N'akụkụ a, a ga-ezere nchịkwa nke moxifloxacin na ndị ọrịa nwere obere oge QT agbatị, hypokalemia na-adịghị edozi, yana ndị na-enweta ọgwụ antiarrhythmic nke IA (quinidine, procainamide) ma ọ bụ klas III (amiodarone, sotalol), ebe ọ bụ na ahụmịhe nke iji moxifloxacin na ndị a. ndị ọrịa bụ ọrịa anụ ahụ.

Ekwesịrị iji nlezianya kee Moxifloxacin, ebe ọ bụ

Agaghị enwe ike ịgbakwunye mmetụta mgbakwunye moxifloxacin na ọnọdụ ndị a:

- n'ime ndị ọrịa na - anata ọgwụgwọ ọgwụ ike na - agbatị oge nke QT (cisapride, erythromycin,

ọgwụ antipsychotic, ọgwụ tricyclic antidepressants),

- n'ime ndị ọrịa nwere ọnọdụ ihe na-emetụta arrhythmias, dị ka bradycardia dị nnukwu ọgwụ, oke myocardial ischemia,

- n'ime ndị ọrịa nwere ọrịa cirrhosis, ebe ọ bụ na ọnụnọ nke ndọtị QT na ha enweghị ike ịpụ,

- n'ime ụmụ nwanyị ma ọ bụ ndị ọrịa agadi, ndị nwere ike ị sensitiveụbiga ọgwụ ike na ịgbatị oge QT. A kọọrọ akụkọ banyere ọrịa ịba ọcha n'anya zuru oke, nwere ike ibute ọrịa imeju na-eyi ndụ egwu, gụnyere ọnwụ. Ọ bụrụ na ihe ịrịba ama nke imeju na-apụta, ndị ọrịa kwesịrị ịkpọtụrụ dọkịta ozugbo tupu ha agawa ọgwụgwọ.

A kọọrọ ọrịa nke mmeghachi omume anụ ahụ jọgburu onwe, dịka ọmụmaatụ, Stevens-Johnson syndrome ma ọ bụ necrolysis na-egbu egbu (nwere ike igbu ndụ). Ọ bụrụ na mmeghachi ahụ na-apụta n'akụkụ anụ ahụ na / ma ọ bụ akpụkpọ ahụ mucous, ị kwesịrị ịkpọtụrụ dọkịta ozugbo tupu ị gaa n'ihu ọgwụgwọ. Ojiji nke quinolone ogwu jikọtara ya na ihe nwere ike ime nke nwere ike ime ndu. A ga-eji Moxifloxacin kpachara anya na ndị ọrịa nwere ọrịa akwara ozi etiti yana ọnọdụ nke na-enyo enyo na usoro ụjọ akwara dị n'etiti, na-ekwupụta oge ihe ọdịdọ na-eme, ma ọ bụ wedata mbido ọnụ maka mmekpa ahụ.

Ojiji nke ọgwụ nje oke ọgụ, gụnyere moxifloxacin, nwere ihe ọghọm nke ịrịa pseudomembranous colitis metụtara ị antibioticsụ ọgwụ nje. Ekwesịrị iburu nchoputa a n'uche ndị ọrịa na-enwe oke afọ ọsịsa n'oge ọgwụgwọ moxifloxacin. N'okwu a, ekwesịrị ịgwọ ọgwụ kwesịrị ekwesị ozugbo. A na-egbochi ndị ọrịa nwere nnukwu afọ ọsịsa na ọgwụ mgbochi ndị na-egbochi motility eriri afọ.

Ekwesịrị iji Moxifloxacin jiri nlezianya mee ihe na ndị ọrịa nwere Gravis myasthenia gravis, ebe ọgwụ ahụ nwere ike ime ka mgbaàmà nke ọrịa a ka njọ.

N'oge ọgwụgwọ fluoroquinolones, gụnyere moxifloxacin, karịsịa na ndị agadi na ndị ọrịa na-enweta glucocorticosteroids, mmepe nke akwara na nkwonkwo ụkwụ nwere ike. Na ngosipụta mbụ nke ihe mgbu ma ọ bụ ọnya na saịtị mmerụ ahụ, ekwesịrị ịkwụsị ọgwụ ahụ ma belata aka aka ahụ.

Maka ndị ọrịa nwere ọrịa mbufụt nke akụkụ ahụ nke pelvic (dịka ọmụmaatụ, ejikọtara ya na tubo-ovarian ma ọ bụ ọrịa pelvic) maka onye a na-egosi ọgwụgwọ ọgbụgba, a na-atụ aro iji moxifloxacin na mbadamba 400 mg.

Mgbe ị na-eji quinolones, a na-achọpụta mmeghachi omume fotoensitivity. Agbanyeghị, n'oge usoro ọmụmụ, nyocha ụlọ ọgwụ, yana iji moxifloxacin na omume, enweghị nchọpụta mmeghachi omume. Agbanyeghị, ndị ọrịa na-anata moxifloxacin kwesịrị izere ìhè anyanwụ na ultraviolet radieshon kpọmkwem.

Maka ndị ọrịa na nri sodium dị ala (maka nkụda obi, ọdịda akụrụ, na ọrịa nephrotic), ekwesịrị itinye mgbakwunye sodium yana ngwakọta infusion.